Search Results
Jun 09, 2026, 08:30 ET AllerGene AI Therapeutics Appoints Biotech Industry Veteran Gad Berdugo to Board of Directors
and capital formation makes him an ideal addition to our Board as we advance our in vivo mRNA CAR platform and position the company for its next stage of growth."AllerGene is developing a novel in vivo mRNA CAR platform designed to selectively target mast cells, the key drivers of severe allergic
More news about: AllerGene AI Therapeutics
Jun 08, 2026, 08:00 ET Argo Biopharma to Present Positive Phase II Updated Results of siRNA Therapeutic BW-20805 for HAE at the EAACI 2026 Congress
2. Current treatments require frequent dosing, highlighting the need for long-acting, preventive therapies. BW-20805 targets human hepatic PKK mRNA to inhibit PKK gene expression, offering the potential for effective prevention of HAE attacks with a significant and longer-lasting therapeutic effect.About
More news about: Argo Biopharmaceutical Co., Ltd
Jun 08, 2026, 08:00 ET Waters Launches Industry-First Reversed-Phase Bioseparation Columns to Deliver Up to 3x Faster GLP-1 Characterization and 2x Faster LNP Component Analysis
In GLP-1 receptor agonists and newer mRNA-based therapies such as in vivo CAR T, difficulty resolving impurities can delay time to market, weaken regulatory confidence, and affect patient safety.
More news about: Waters Corporation
Jun 08, 2026, 08:00 ET Waters Launches Industry-First Reversed-Phase Bioseparation Columns to Deliver Up to 3x Faster GLP-1 Characterization and 2x Faster LNP Component Analysis
In GLP-1 receptor agonists and newer mRNA-based therapies such as in vivo CAR T, difficulty resolving impurities can delay time to market, weaken regulatory confidence, and affect patient safety.
More news about: Waters Corporation
Jun 08, 2026, 04:30 ET 2026 ADA | Innovent Presents Multiple Clinical and Preclinical Results of Next-Generation Obesity & Metabolic Pipeline
2662-P)IBI3046 is an INHBE-silencing RNAi therapeutic designed to enhance adipose lipolysis with sustained effects.IBI3046 demonstrated potent and durable mRNA knockdown in hINHBE KI mouse model. In the efficacy study, IBI3046 resulted in a 13% reduction in body weight and a 50% decrease in fat mass relative
More news about: Innovent Biologics
Jun 05, 2026, 09:00 ET Diakonos Oncology Shares Updated DOC1021 GBM Survival Data and Unveils Melanoma Clinical Study at ASCO 2026
patient-derived double-loaded dendritic cell therapy that combines tumor lysate and amplified tumor-derived mRNA. The immunotherapy is made with a patient's own dendritic cells combined with mRNA and proteins prepared from freshly obtained patient tumor specimens.The unique double-loading approach,
More news about: Diakonos Oncology
Jun 04, 2026, 11:19 ET Veterinary Vaccines Market Set to Attain US$ 15.6 Billion Valuation by 2031, Growing at 6% CAGR, Says Wissen Research
important for food security and farm productivity. Increasing pet ownership, growing commercial livestock, and the adoption of advanced vaccine tech like mRNA and recombinant vaccines are also boosting the market. Additionally, government-led vaccination drives and increased efforts to stop diseases such as
More news about: Wissen Research LLC
Jun 04, 2026, 10:30 ET Made Scientific and Pluristyx Launch Integrated iPSC Development & Manufacturing Partnership to Advance Next-Generation iPSC-derived Cell Therapies
delivering a comprehensive platform designed to accelerate therapeutic development with unmatched speed, safety, and scalability. Leveraging proprietary mRNA bulk reprogramming and a polyclonal iPSC approach, Pluristyx produces genetically younger, more stable, and highly expandable cells. The company's portfolio
More news about: Made Scientific, Inc.
Jun 04, 2026, 07:00 ET HotSpot Therapeutics Presents Preclinical Data from Small Molecule IRF5 Inhibitor Program at EULAR 2026
as compared to key benchmarks.In an in vivo mouse model, HotSpot's IRF5 inhibitors demonstrated dose-dependent inhibition of cytokines and mRNA response, as well as dose-dependent down-regulation of interferon and IRF5-driven gene signatures, confirming pathway-level modulation in this model.In
More news about: HotSpot Therapeutics
Jun 02, 2026, 04:19 ET Skyhawk Therapeutics gibt Zwölfmonats-Zwischenergebnisse der klinischen Phase-1/2-Studie zu SKY-0515 bei der Huntington-Krankheit bekannt
SKY-0515 führte zu einer dosisabhängigen Verringerung des mutierten Huntingtin-Proteins (mHTT) im Blut um bis zu 69 % sowie zu einer Verringerung der PMS1-mRNA um bis zu 26 %. Das mutierte Huntingtin ist das Hauptprotein, das für die Pathologie der Huntington-Krankheit verantwortlich ist, während PMS1 ein wesentlicher
More news about: Skyhawk Therapeutics
Jun 01, 2026, 12:00 ET Eclipsebio Expands eCOMPASS™ Platform with eSENSE Break™ to Map RNA Fragmentation at Nucleotide Resolution
uses next-generation sequencing to map RNA fragmentation sites at single-nucleotide resolution across linear mRNA, self-amplifying RNA, and circular RNA therapeutics.For linear mRNA, eSENSE Break pinpoints fragmentation hotspots across the sequence, giving positional data to refine designs
More news about: Eclipsebio
Jun 01, 2026, 08:11 ET Cancer Vaccine Sustains 49 Percent Melanoma Reduction After 5 Years
in the Department of Medicine at NYU Grossman School of Medicine."Our findings also serve as encouragement to cancer researchers globally that mRNA vaccines like intismeran could work well in combination with immunotherapy for other cancers whose high rates of mutations have proven difficult to
More news about: NYU Langone Health System
Jun 01, 2026, 06:30 ET Skyhawk Therapeutics Announces Twelve-Month Interim Results from Phase 1/2 Clinical Trial of SKY-0515 in Huntington's Disease
Treatment with SKY-0515 resulted in dose-dependent reductions in mutant huntingtin (mHTT) protein in blood of up to 69% as well as reductions in PMS1 mRNA of up to 26%. Mutant huntingtin is the primary protein responsible for HD pathology, while PMS1 is a key driver of somatic CAG repeat expansion associated
More news about: Skyhawk Therapeutics
Jun 01, 2026, 06:30 ET Skyhawk Therapeutics Announces Twelve-Month Interim Results from Phase 1/2 Clinical Trial of SKY-0515 in Huntington's Disease
Treatment with SKY-0515 resulted in dose-dependent reductions in mutant huntingtin (mHTT) protein in blood of up to 69% as well as reductions in PMS1 mRNA of up to 26%. Mutant huntingtin is the primary protein responsible for HD pathology, while PMS1 is a key driver of somatic CAG repeat expansion associated
More news about: Skyhawk Therapeutics
May 31, 2026, 09:00 ET HARMONi-6 Demonstrates Significant Overall Survival Benefit (HR=0.66): Ivonescimab Plus Chemotherapy Superior to PD-1 Plus Chemotherapy in First-Line sq-NSCLC Landmark Results to Be Presented at ASCO 2026 Plenary Session
platform, AI-powered drug R&D platform, Dual-Shield ADC technology platform, Dual-Lock T-cell engager (TCE) technology platform, Tissue-Smart siRNA/mRNA technology platform, and cell therapy technology platforms. Supported by a global-standard GMP manufacturing infrastructure and a highly efficient,
More news about: Akeso, Inc.
May 29, 2026, 08:00 ET SK bioscience Board Approves Financing Plan Supported by Korea Growth Fund
infectious disease-focused pipeline, including universal COVID-19 vaccines, microneedle patch influenza vaccines, RSV preventive antibody therapeutics, and mRNA vaccine platforms. Earlier this year, the company relocated its headquarters and research center to Songdo, Incheon, integrating R&D, process development
More news about: SK bioscience
May 28, 2026, 08:54 ET Florida Cancer Specialists & Research Institute Advances the Future of Cancer Care
in advanced NSCLC.Judy Wang, MDA phase 1, first-in-human study of DS5361, a small-molecule, nonsense-mediated mRNA decay (NMD) inhibitor in patients with advanced/metastatic solid tumors (parts 1 and 2).
More news about: Florida Cancer Specialists & Research Institute
May 26, 2026, 08:18 ET Hoth Therapeutics Awarded U.S. Patent for Cancer-Fighting HT-KIT Oncology Platform
50 linked nucleosides directed to splicing-relevant regions of the MS4A6A pre-mRNA, including intron 3, exon 4, and the intron 3/exon 4 junction, together with pharmaceutical compositions and methods for modulating MS4A6A mRNA splicing in cells or tissues. Hybridization of the disclosed oligomers is
More news about: Hoth Therapeutics, Inc.
May 26, 2026, 06:45 ET Vaccine Company to be acquired by Lilly to advance best-in-class vaccine candidates for Epstein-Barr Virus and other infectious diseases
next-generation antigen engineering to vaccine science. The company's proprietary In Vivo Nanoparticle (IVN) technologies are designed to combine the strengths of mRNA and virus-like particle approaches to enable durable, multivalent immune responses to challenging viral targets. Vaccine Company is advancing a pipeline
More news about: Vaccine Company
May 26, 2026, 00:35 ET Over 40 Studies Featuring Akeso's Innovative Oncology Agents to Be Presented at ASCO 2026: Ivonescimab's HARMONi-6 Overall Survival Data Selected for Plenary Session
platform, AI-powered drug R&D platform, Dual-Shield ADC technology platform, Dual-Lock T-cell engager (TCE) technology platform, Tissue-Smart siRNA/mRNA technology platform, and cell therapy technology platforms. Supported by a global-standard GMP manufacturing infrastructure and a highly efficient,
More news about: Akeso, Inc.
May 23, 2026, 10:00 ET Meet Clicklinks: The Innovation Hub for Original Drug Discovery
scientific scrutiny. Not luck — data.Gateway 4: Innovative TechnologiesA gathering place for cutting-edge technology platforms: mRNA-encoded antibodies, AI-driven molecular generation, organoid evaluation systems, and more. The frontier explorer's arsenal is always open to you.Gateway
More news about: Sanyou Bio
May 20, 2026, 10:00 ET Sanyou Bio Launches SAI-DA 1.0, the AI-Drug Accelerator
volumesCore Technology AccelerationSimultaneous advancement of cutting-edge technologies including DAC, AOC, POC, mRNA-mAb, siRNA, and CAR-T/TCR cell therapiesDevelopment of automated, intelligent "lights-out factories" and BCT-CR drug screening systemsEstablishment
More news about: Sanyou Bio
May 20, 2026, 06:57 ET METiS TechBio to Present Late-Breaking Data on Near-Complete Cardiomyocyte Delivery at CRS 2026
under the NanoForge platform to identify LNPs with specific tissue tropism. The research team evaluated candidate LNPs in mTmG mouse models, using Cre-mRNA to induce eGFP expression as a readout for functional intracellular delivery. After identifying lead lipids with heart-specific tropism, the team further
More news about: METiS TechBio
May 19, 2026, 08:00 ET etherna's mRNA and LNP Platforms Propel Dropshot Therapeutics' Renal Target to the Clinical Stage
Belgium, May 19, 2026 /PRNewswire/ -- etherna, a leading provider of cutting-edge mRNA and lipid nanoparticle (LNP) technology across the biotech and pharma industry, today announces a major milestone in its ongoing partnership with Dropshot
More news about: etherna
May 17, 2026, 21:12 ET ACROBiosystems Innovation Day in Zürich bringt führende Köpfe zur Erkundung neuer Biotech-Grenzen zusammen
bei der Herstellung durch die Immobilisierung von Enzymen. In ihrem Vortrag „Immobilized Enzymes for Smart Biologics Manufacturing: Applications in mRNA and ADC Production" stellten sie eine patentierte Technologie vor, die die Stabilität und Wiederverwendbarkeit von Enzymen erhöht. Sie stellten zwei
More news about: ACROBiosystems Group